"The Phase II interim data for AZD1222 suggests older individuals have lower reactogenicity whilst still maintaining a robust immune response", said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D in a statement.
Labelled as "ChAdOx1 nCoV-19", the vaccine candidate is an "adenovirus-vectored vaccine", meaning that it consists of engineered viruses that transport a virus' gene (in this case from SARS-Cov-2, the virus which causes the COVID-19 disease) into our bodies.
The researchers said that two doses of CoronaVac at different concentrations and using different dosing schedules had goof tolerance and moderately immunogenic in healthy adults aged between 18-59 years.
Trudeau was asked directly whether Elliott's coronavirus vaccine numbers were wrong, but he sidestepped mentioning the Ontario minister in his response.More news: WHO advises against Gilead's remdesivir for all hospitalised COVID-19 patients
The ministry had said that the trials of COVID-19 vaccines have entered into its third phase on the global level and all countries started advance booking for the vaccines expected to be introduced in the first and second quarters of 2021.
'Older adults are a priority group for COVID-19 vaccination, because they are at increased risk of severe disease, but we know that they tend to have poorer vaccine responses'.
"One of the most exciting things from our study was that the vaccine stimulated really good antibody production".
It added that Pakistan contacted Gavi, the Vaccine Alliance, for getting free-of-cost vaccines or its availability on discounted prices. The incidence of adverse reactions in the 3 micrograms and 6 microgram groups were similar. "We hope that this means our vaccine will help to protect some of the most vulnerable people in society, but further research will be needed before we can be sure".More news: U.S. election: Georgia vote audit confirms Biden victory
Larger studies are now underway to evaluate immunogenicity, safety and efficacy in older adults with a wider range of comorbidities.
Because only a Phase 3 trial includes enough people - and runs for long enough for the volunteers included to actually catch Covid - and therefore prove whether your vaccine works or not. There were also spike-specific T-cell responses that peaked 14 days after prime vaccination which were similar in all age and dosage groups.
The authors also note that the oldest age group in their study - whose average age is 73-74 - may not represent the general population because they happened to have relatively few underlying health conditions, given their age. The next step will be to see if this translates into protection from the disease itself'.
He said, "We will need all of them to protect people around the globe".More news: Capacity 'stretched' as Nunavut dealt with soaring COVID-19 cases: Doctor's best